Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 4Patient Satisfaction 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Rectal Neoplasms 1Patient Participation 1Ileus 1

Interventions

pembrolizumab 3atezolizumab 2Sugammadex 2Saline Solution 2Paclitaxel 2Neostigmine 2Gemcitabine 2Cetuximab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1lenvatinib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1delta 24-sterol reductase 1daratumumab 1cabozantinib 1abemaciclib 1Zoledronic Acid 1Water 1Valproic Acid 1Urinary Diversion 1Ultrasonography 1Trastuzumab 1Tomography, Optical Coherence 1Tissue Banks 1Therapeutics 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urologic Neoplasms × Urinary Diversion × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡